GRFS
Grifols, S.A.
Price Chart
Latest Quote
$7.99
+0.07 (+0.88%)
Current Price
| Previous Close | $7.92 |
| Open | $7.89 |
| Day High | $8.00 |
| Day Low | $7.88 |
| Volume | 295,553 |
Stock Information
Note: Financial values converted from EUR to USD
| Quarterly Dividend / Yield | $0.11 / 1.34% |
| Shares Outstanding | 258.22M |
| Quarterly Dividend Yield | 1.34% |
| Quarterly Dividend | $0.11 |
| Total Debt | $10.42B |
| Cash Equivalents | $598.13M |
| Revenue | $8.27B |
| Net Income | $503.45M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $5.44B |
| P/E Ratio | 9.86 |
| EPS (TTM) | $0.81 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $22.03B |
| Sales | $8.27B |
| Income | $503.45M |
| Book/sh | $4.58 |
| Cash/sh | $2.08 |
| Employees | 25K |
Financial Ratios
| Quick Ratio | 0.70 |
| Current Ratio | 2.37 |
| Debt/Eq | 117.24 |
| EPS Growth TTM | 31.30% |
Returns & Margins
| ROA | 4.23% |
| ROE | 6.93% |
| Gross Margin | 37.79% |
| Operating Margin | 15.90% |
| Profit Margin | 6.09% |
Ownership
| Institutional Ownership | 57.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 6.00 |
| PEG | 0.19 |
| P/S | 0.73 |
| P/B | 1.75 |
Analyst Data
| Recommendation | buy |
| Target Price | $10.37 |
Technical Indicators
| SMA20 | $7.49 |
| SMA50 | $7.58 |
| SMA200 | $7.95 |
| RSI | 65.03 |
| ATR | 0.2043 |
| Shares Float | 836.45M |
| Short Ratio | 11.37 |
| Volatility | 1.20 |
| Rel Volume | 0.52 |
Performance History
| Week | +5.97% |
| Month | +7.83% |
| Quarter | -1.96% |
| 6 Months | +0.34% |
| YTD | -12.36% |
| Year | -14.40% |
| 3 Years | +1.75% |
| 5 Years | -39.47% |
| 10 Years | -37.29% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $7.99 | 295,553 |
| 2026-10-26 | $7.92 | 845,900 |
| 2026-10-23 | $7.56 | 992,300 |
| 2026-10-22 | $7.45 | 482,500 |
| 2026-10-21 | $7.50 | 310,900 |
| 2026-10-20 | $7.54 | 369,100 |
| 2026-10-19 | $7.64 | 1,464,300 |
| 2026-10-16 | $7.64 | 872,400 |
| 2026-10-15 | $7.54 | 907,100 |
| 2026-10-14 | $7.24 | 538,500 |
| 2026-10-13 | $7.17 | 439,500 |
| 2026-10-12 | $7.37 | 266,100 |
| 2026-10-09 | $7.46 | 330,600 |
| 2026-10-08 | $7.41 | 368,100 |
| 2026-10-07 | $7.50 | 260,700 |
| 2026-10-06 | $7.52 | 326,100 |
| 2026-10-05 | $7.41 | 492,800 |
| 2026-10-02 | $7.31 | 390,400 |
| 2026-10-01 | $7.30 | 623,100 |
| 2026-09-30 | $7.31 | 773,000 |
| 2026-09-29 | $7.30 | 485,000 |
| 2026-09-28 | $7.41 | 597,100 |
About Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
đ° Latest News
No news articles available at the moment. Check back later for updates on GRFS.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,870,238,982 | $4,597,235,966 | $4,235,478,884 | $3,962,851,107 |
| Cost Of Revenue | $5,240,983,818 | $4,963,486,926 | $4,616,334,943 | $4,325,645,152 |
| Total Revenue | $8,452,982,261 | $8,102,459,870 | $7,405,908,966 | $6,812,680,154 |
| Operating Revenue | $8,179,979,245 | $7,868,778,277 | $7,176,721,250 | $6,531,627,482 |
| Expenses | ||||
| Interest Expense | $647,118,259 | $676,328,458 | $579,710,107 | $499,430,369 |
| Total Expenses | $7,047,522,292 | $6,804,852,944 | $6,599,258,081 | $6,049,891,753 |
| Other Income Expense | $-34,827,545 | $-11,234,692 | $53,926,522 | $136,748,671 |
| Net Non Operating Interest Income Expense | $-679,698,866 | $-787,551,909 | $-629,142,752 | $-519,789,877 |
| Total Other Finance Cost | $70,778,560 | $160,656,096 | $119,087,735 | $58,399,052 |
| Interest Expense Non Operating | $647,118,259 | $676,328,458 | $579,710,107 | $499,430,369 |
| Operating Expense | $1,806,538,474 | $1,841,366,019 | $1,982,923,138 | $1,724,246,602 |
| Other Operating Expenses | $-1,123,469 | - | $-3,370,408 | $-24,980,338 |
| General And Administrative Expense | $1,194,247,760 | $1,284,125,296 | $1,422,312,007 | $1,244,567,945 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $451,634,618 | $176,384,664 | $47,185,706 | $207,881,123 |
| Net Interest Income | $-679,698,866 | $-787,551,909 | $-629,142,752 | $-519,789,877 |
| Interest Income | $38,197,953 | $49,432,645 | $69,655,090 | $38,039,544 |
| Normalized Income | $472,642,369 | $215,986,954 | $60,520,086 | $191,629,274 |
| Net Income From Continuing And Discontinued Operation | $451,634,618 | $176,384,664 | $47,185,706 | $207,881,123 |
| Total Operating Income As Reported | $1,396,472,216 | $1,339,175,286 | $878,552,914 | $879,042,747 |
| Net Income Common Stockholders | $451,634,618 | $176,384,664 | $47,185,706 | $207,881,123 |
| Net Income | $451,634,618 | $176,384,664 | $47,185,706 | $207,881,123 |
| Net Income Including Noncontrolling Interests | $561,734,600 | $239,298,940 | $183,125,480 | $278,510,262 |
| Net Income Continuous Operations | $561,734,600 | $239,298,940 | $183,125,480 | $278,510,262 |
| Pretax Income | $690,933,558 | $498,820,325 | $231,434,655 | $379,747,195 |
| Special Income Charges | $-3,370,408 | $-10,111,223 | $0 | $0 |
| Earnings From Equity Interest | $-8,987,754 | $41,568,360 | $70,778,560 | $114,589,365 |
| Interest Income Non Operating | $38,197,953 | $49,432,645 | $69,655,090 | $38,039,544 |
| Operating Income | $1,405,459,969 | $1,297,606,926 | $806,650,886 | $762,788,401 |
| Depreciation Amortization Depletion Income Statement | $134,816,304 | $125,828,550 | $120,211,204 | $98,929,327 |
| Depreciation And Amortization In Income Statement | $134,816,304 | $125,828,550 | $120,211,204 | $98,929,327 |
| Gross Profit | $3,211,998,443 | $3,138,972,945 | $2,789,574,024 | $2,487,035,003 |
| Per Share | ||||
| Diluted EPS | $0.66 | $0.26 | $0.10 | $0.35 |
| Basic EPS | $0.66 | $0.26 | $0.10 | $0.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $-4,832,041 | $-13,200,763 | $-3,517,658 | $5,907,457 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,869,452,749 | $1,720,031,345 | $1,329,064,064 | $1,318,741,629 |
| Total Unusual Items | $-25,839,792 | $-52,803,052 | $-16,852,038 | $22,159,307 |
| Total Unusual Items Excluding Goodwill | $-25,839,792 | $-52,803,052 | $-16,852,038 | $22,159,307 |
| Reconciled Depreciation | $505,561,140 | $492,079,510 | $501,067,263 | $461,723,372 |
| EBITDA (Bullshit earnings) | $1,843,612,957 | $1,667,228,293 | $1,312,212,026 | $1,340,900,935 |
| EBIT | $1,338,051,817 | $1,175,148,783 | $811,144,762 | $879,177,563 |
| Diluted Average Shares | $765,726,436 | $763,865,488 | $763,685,260 | $763,740,139 |
| Basic Average Shares | $764,534,908 | $763,586,683 | $763,685,260 | $763,740,139 |
| Diluted NI Availto Com Stockholders | $451,634,618 | $176,384,664 | $47,185,706 | $207,881,123 |
| Minority Interests | $-110,099,982 | $-62,914,275 | $-135,939,773 | $-70,629,138 |
| Tax Provision | $129,198,958 | $259,521,385 | $48,309,176 | $101,236,933 |
| Write Off | $3,370,408 | $10,111,223 | $0 | $0 |
| Gain On Sale Of Security | $-22,469,384 | $-42,691,830 | $-16,852,038 | $22,159,307 |
| Research And Development | $478,597,879 | $431,412,173 | $443,770,334 | $405,729,667 |
| Selling General And Administration | $1,194,247,760 | $1,284,125,296 | $1,422,312,007 | $1,244,567,945 |
| Other Gand A | $1,194,247,760 | $1,284,125,296 | $1,422,312,007 | $1,244,567,945 |
| Gain On Sale Of Ppe | - | - | $-28,078,866 | $-20,448,263 |
| Salaries And Wages | - | - | $594,072,537 | $530,741,455 |
Fetched: 2026-10-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-4,819,682,868 | $-4,994,944,063 | $-4,792,660,063 | $-4,844,997,999 |
| Total Assets | $22,145,824,870 | $24,047,858,226 | $23,583,981,164 | $23,850,783,753 |
| Total Non Current Assets | $16,445,342,150 | $17,612,626,648 | $16,695,973,523 | $18,580,899,813 |
| Non Current Prepaid Assets | $17,975,507 | $10,111,223 | $9,967,419 | $10,422,424 |
| Non Current Deferred Assets | $467,363,187 | $384,226,466 | $337,410,381 | $196,520,603 |
| Non Current Deferred Taxes Assets | $467,363,187 | $384,226,466 | $337,410,381 | $196,520,603 |
| Non Current Note Receivables | $149,421,404 | $22,469,384 | $153,495,103 | $123,241,201 |
| Financial Assets | $0 | $1,123,469 | $1,171,778 | $30,367,372 |
| Investmentin Financial Assets | $407,819,320 | $516,795,832 | $33,854,621 | $557,929,410 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $2,246,938 | $5,617,346 | $7,864 | - |
| Goodwill And Other Intangible Assets | $10,741,489,021 | $11,604,313,367 | $10,823,865,153 | $11,190,939,615 |
| Other Intangible Assets | $3,064,823,978 | $3,287,270,879 | $3,181,884,974 | $3,313,275,821 |
| Current Assets | $5,700,482,721 | $6,435,231,578 | $6,888,007,641 | $5,269,883,940 |
| Other Current Assets | $73,025,498 | $80,889,782 | $83,071,560 | $92,885,063 |
| Hedging Assets Current | $0 | $6,740,815 | $26,563,306 | $14,188,293 |
| Restricted Cash | $26,963,261 | $0 | - | - |
| Prepaid Assets | $10,111,223 | $11,234,692 | $5,027,525 | $21,786,315 |
| Inventory | $3,702,954,483 | $3,999,550,352 | $3,912,368,019 | $3,635,557,566 |
| Receivables | $961,689,635 | $1,212,223,267 | $1,024,825,234 | $869,787,608 |
| Other Receivables | $135,939,773 | $59,543,868 | $96,558,807 | $121,711,036 |
| Taxes Receivable | $80,889,782 | $120,211,204 | $89,652,842 | $63,792,828 |
| Loans Receivable | $13,481,630 | $240,422,409 | $113,848,998 | $53,927 |
| Accounts Receivable | $731,378,449 | $792,045,786 | $724,764,586 | $684,283,744 |
| Allowance For Doubtful Accounts Receivable | $-25,839,792 | $-23,592,853 | $-35,474,663 | $-36,277,944 |
| Gross Accounts Receivable | $757,218,241 | $815,638,639 | $760,239,249 | $720,120,164 |
| Cash Cash Equivalents And Short Term Investments | $925,738,621 | $1,124,592,669 | $611,732,350 | $651,882,892 |
| Cash And Cash Equivalents | $899,898,829 | $1,100,999,816 | $594,963,449 | $617,017,149 |
| Cash Equivalents | $8,987,754 | $5,617,346 | $7,309,291 | $5,617 |
| Cash Financial | $890,911,076 | $1,095,382,470 | $587,654,158 | $615,637,529 |
| Other Non Current Assets | - | $153,915,280 | $152,380,621 | $139,524,763 |
| Non Current Accounts Receivable | - | $66,285 | - | - |
| Assets Held For Sale Current | - | $0 | $1,224,419,648 | $5,582,518 |
| Debt | ||||
| Net Debt | $8,631,613,864 | $8,977,642,377 | $10,484,268,501 | $9,195,822,343 |
| Total Debt | $10,747,106,367 | $11,361,644,020 | $12,327,774,729 | $10,953,965,134 |
| Long Term Debt And Capital Lease Obligation | $10,159,531,976 | $10,611,166,594 | $11,217,889,395 | $10,188,575,901 |
| Long Term Debt | $9,070,890,321 | $9,459,610,664 | $10,089,671,290 | $9,161,064,453 |
| Current Debt And Capital Lease Obligation | $587,574,392 | $750,477,426 | $1,109,885,334 | $765,389,232 |
| Current Debt | $460,622,372 | $619,031,529 | $989,560,659 | $650,395,419 |
| Other Current Borrowings | $460,622,372 | $619,031,529 | $989,560,659 | $650,395,419 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,604,088,543 | $14,379,282,291 | $15,142,576,253 | $14,889,848,486 |
| Total Non Current Liabilities Net Minority Interest | $11,335,804,228 | $11,957,082,696 | $12,530,012,666 | $12,621,254,094 |
| Other Non Current Liabilities | $56,173,460 | $52,803,052 | $54,543,306 | $11,318,019,711 |
| Derivative Product Liabilities | $1,123,469 | $0 | $12,358 | $4,497,247 |
| Non Current Deferred Liabilities | $985,282,488 | $1,152,679,399 | $1,126,205,971 | $1,179,581,993 |
| Non Current Deferred Taxes Liabilities | $967,306,981 | $1,136,950,830 | $1,110,694,232 | $1,162,591,768 |
| Current Liabilities | $2,268,284,315 | $2,422,199,595 | $2,612,563,587 | $2,268,594,392 |
| Other Current Liabilities | $89,877,536 | $47,185,706 | $48,060,889 | $1,173,305,170 |
| Current Deferred Liabilities | $38,197,953 | $48,309,176 | $44,032,128 | $42,505,334 |
| Payables And Accrued Expenses | $1,513,313,012 | $1,532,411,989 | $1,356,876,667 | $1,031,994,091 |
| Payables | $1,513,313,012 | $1,532,411,989 | $1,356,876,667 | $1,031,994,091 |
| Other Payable | $512,301,955 | $478,597,879 | $391,002,109 | $129,116,945 |
| Total Tax Payable | $56,173,460 | $96,618,351 | $41,312,209 | $17,623,861 |
| Income Tax Payable | $28,086,730 | $68,531,621 | $16,316,143 | $17,623,861 |
| Accounts Payable | $944,837,597 | $957,195,758 | $924,562,349 | $885,253,285 |
| Equity | ||||
| Common Stock Equity | $5,921,806,153 | $6,609,369,304 | $6,031,205,090 | $6,345,941,616 |
| Total Equity Gross Minority Interest | $8,541,736,328 | $9,668,575,935 | $8,441,404,911 | $8,960,935,267 |
| Stockholders Equity | $5,921,806,153 | $6,609,369,304 | $6,031,205,090 | $6,345,941,616 |
| Gains Losses Not Affecting Retained Earnings | $4,573,643,113 | $5,426,356,236 | $4,997,723,526 | $5,370,644,522 |
| Other Equity Adjustments | $4,694,977,787 | $4,544,432,914 | $4,532,481,449 | $4,544,021,724 |
| Retained Earnings | $337,040,760 | $176,384,664 | $47,542,970 | $0 |
| Long Term Equity Investment | $108,976,512 | $77,519,375 | $473,837,740 | $1,682,910,799 |
| Other | ||||
| Treasury Shares Number | $7,841,361 | $8,028,091 | $9,507,503 | $10,273,243 |
| Ordinary Shares Number | $764,605,401 | $764,418,672 | $762,939,259 | $762,173,520 |
| Share Issued | $772,446,762 | $772,446,762 | $772,446,762 | $772,446,762 |
| Tangible Book Value | $-4,819,682,868 | $-4,994,944,063 | $-4,792,660,063 | $-4,844,997,999 |
| Invested Capital | $15,453,318,846 | $16,688,011,497 | $17,110,437,039 | $6,345,941,616 |
| Working Capital | $3,432,198,406 | $4,013,031,982 | $4,275,444,054 | $3,001,289,547 |
| Capital Lease Obligations | $1,215,593,674 | $1,283,001,826 | $1,248,542,779 | $1,142,505,262 |
| Total Capitalization | $14,992,696,474 | $16,068,979,968 | $16,120,876,380 | $6,345,941,616 |
| Minority Interest | $2,619,930,174 | $3,059,206,632 | $2,410,199,821 | $2,614,993,651 |
| Foreign Currency Translation Adjustments | $-11,234,692 | $902,145,768 | $465,242,077 | $826,622,798 |
| Unrealized Gain Loss | $-110,099,982 | $-20,222,446 | $0 | $0 |
| Treasury Stock | $147,174,465 | $151,668,342 | $171,607,673 | $182,249,174 |
| Additional Paid In Capital | $1,023,480,441 | $1,023,480,441 | $1,023,174,858 | $1,023,174,858 |
| Capital Stock | $134,816,304 | $134,816,304 | $134,371,410 | $134,371,410 |
| Common Stock | $134,816,304 | $134,816,304 | $134,371,410 | $134,371,410 |
| Non Current Deferred Revenue | $17,975,507 | $15,728,569 | $15,511,739 | $16,990,225 |
| Long Term Capital Lease Obligation | $1,088,641,655 | $1,151,555,930 | $1,128,218,104 | $1,027,511,449 |
| Long Term Provisions | $133,692,835 | $140,433,650 | $131,361,636 | $123,652,391 |
| Current Deferred Revenue | $38,197,953 | $48,309,176 | $44,032,128 | $42,505,334 |
| Current Capital Lease Obligation | $126,952,020 | $131,445,896 | $120,324,675 | $114,993,813 |
| Current Provisions | $39,321,422 | $43,815,299 | $53,708,569 | $63,295,131 |
| Investments And Advances | $516,795,832 | $594,315,207 | $507,692,361 | $2,240,840,209 |
| Available For Sale Securities | $405,572,381 | $511,178,486 | $33,846,757 | $557,929,410 |
| Goodwill | $7,676,665,044 | $8,317,042,488 | $7,641,980,179 | $7,877,663,795 |
| Net PPE | $4,552,297,198 | $4,842,152,252 | $4,709,990,706 | $4,813,074,622 |
| Accumulated Depreciation | $-2,991,798,480 | $-2,965,958,688 | $-2,556,866,478 | $-2,340,691,905 |
| Gross PPE | $7,544,095,678 | $7,808,110,940 | $7,266,857,184 | $4,813,074,622 |
| Leases | $1,462,756,898 | $1,488,596,690 | $1,366,204,832 | $1,252,279,438 |
| Construction In Progress | $815,638,639 | $901,022,298 | $1,023,109,696 | $986,872,197 |
| Machinery Furniture Equipment | $3,907,425,878 | $4,035,501,366 | $3,605,874,386 | $3,486,646,217 |
| Land And Improvements | $1,358,274,263 | $1,382,990,585 | $1,271,668,269 | $1,298,063,054 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-111,223,451 | $-168,520,380 | - | - |
| Finished Goods | $1,181,889,598 | $1,407,706,908 | $1,325,708,261 | $904,321,927 |
| Work In Process | $1,580,721,164 | $1,660,487,478 | $1,359,493,227 | $1,496,061,019 |
| Raw Materials | $1,051,567,171 | $1,099,876,347 | $1,227,166,531 | $1,196,243,041 |
| Other Short Term Investments | $25,839,792 | $23,592,853 | $16,768,901 | $34,865,743 |
| Employee Benefits | - | - | $112,525,552 | $105,685,871 |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | $112,525,552 | $105,685,871 |
| Other Properties | - | - | - | $4,813,074,622 |
Fetched: 2026-10-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $701,044,781 | $595,438,676 | $-104,482,636 | $-442,982,782 |
| Operating Activities | ||||
| Operating Cash Flow | $1,176,272,252 | $1,013,369,218 | $243,792,816 | $-1,603,191 |
| Cash Flow From Continuing Operating Activities | $1,176,272,252 | $1,013,369,218 | $243,792,816 | $-1,603,191 |
| Operating Gains Losses | $11,234,692 | $-40,444,891 | $-62,914,275 | $-116,534,090 |
| Investing Activities | ||||
| Capital Expenditure | $-475,227,472 | $-417,930,542 | $-348,275,452 | $-441,379,592 |
| Investing Cash Flow | $-650,488,667 | $995,393,711 | $-442,646,865 | $-2,242,582,710 |
| Cash Flow From Continuing Investing Activities | $-650,488,667 | $995,393,711 | $-442,646,865 | $-2,242,582,710 |
| Net Other Investing Changes | - | $1,757,105,829 | - | $102,654,751 |
| Financing Activities | ||||
| Financing Cash Flow | $-594,315,207 | $-1,526,794,643 | $193,236,702 | $-185,261,195 |
| Cash Flow From Continuing Financing Activities | $-594,315,207 | $-1,526,794,643 | $193,236,702 | $-185,261,195 |
| Net Other Financing Charges | $-316,818,314 | $-1,400,966,092 | $323,559,130 | $-63,546,788 |
| Cash Dividends Paid | $-143,804,058 | $-1,123,469 | $0 | $-665,094 |
| Common Stock Dividend Paid | $-143,804,058 | $-1,123,469 | $0 | - |
| Repurchase Of Capital Stock | - | $0 | $0 | $-3,886,080 |
| Net Common Stock Issuance | - | $0 | $0 | $-3,886,080 |
| Other | ||||
| Repayment Of Debt | $-133,692,835 | $-124,705,081 | $-130,322,427 | $-117,163,232 |
| End Cash Position | $926,862,090 | $1,100,999,816 | $594,315,207 | $617,017,149 |
| Beginning Cash Position | $1,100,999,816 | $594,315,207 | $616,784,591 | $3,006,523,790 |
| Effect Of Exchange Rate Changes | $-105,606,105 | $24,716,322 | $-16,852,038 | $39,940,454 |
| Changes In Cash | $-68,531,621 | $481,968,287 | $-5,617,346 | $-2,429,447,095 |
| Net Issuance Payments Of Debt | $-133,692,835 | $-124,705,081 | $-130,322,427 | $-117,163,232 |
| Net Long Term Debt Issuance | $-133,692,835 | $-124,705,081 | $-130,322,427 | $-117,163,232 |
| Long Term Debt Payments | $-133,692,835 | $-124,705,081 | $-130,322,427 | $-117,163,232 |
| Net Investment Purchase And Sale | $-58,420,398 | $-49,432,645 | $-87,630,598 | $-184,985,945 |
| Sale Of Investment | $5,617,346 | $0 | $16,852,038 | $0 |
| Purchase Of Investment | $-64,037,744 | $-49,432,645 | $-104,482,636 | $-184,985,945 |
| Net Business Purchase And Sale | $-121,334,674 | $-321,312,191 | $-32,580,607 | $-1,722,574,879 |
| Purchase Of Business | $-121,334,674 | $-321,312,191 | $-32,580,607 | $-1,722,574,879 |
| Net Intangibles Purchase And Sale | $-177,508,134 | $-156,162,219 | $-96,618,351 | $-122,535,662 |
| Purchase Of Intangibles | $-177,508,134 | $-156,162,219 | $-96,618,351 | $-122,535,662 |
| Net PPE Purchase And Sale | $-293,225,461 | $-234,805,063 | $-225,817,309 | $-315,140,975 |
| Sale Of PPE | $4,493,877 | $26,963,261 | $25,839,792 | $3,702,954 |
| Purchase Of PPE | $-297,719,338 | $-261,768,324 | $-251,657,101 | $-318,843,929 |
| Taxes Refund Paid | $-189,866,295 | $-197,730,579 | $-178,631,603 | $-220,689,796 |
| Interest Received Cfo | $11,234,692 | $12,358,161 | $15,728,569 | $4,554,544 |
| Interest Paid Cfo | $-597,685,614 | $-641,500,913 | $-594,315,207 | $-393,649,003 |
| Change In Working Capital | $-34,827,545 | $25,839,792 | $-407,819,320 | $-656,500,350 |
| Change In Other Current Assets | $4,493,877 | $11,234,692 | $14,605,100 | $-2,530,053 |
| Change In Payables And Accrued Expense | $105,606,105 | $32,580,607 | $116,840,797 | $142,137,953 |
| Change In Payable | $105,606,105 | $32,580,607 | $116,840,797 | $142,137,953 |
| Change In Inventory | $-108,976,512 | $29,210,199 | $-461,745,841 | $-709,046,128 |
| Change In Receivables | $-35,951,014 | $-47,185,706 | $-77,519,375 | $-87,062,122 |
| Other Non Cash Items | $724,637,634 | $781,934,563 | $625,772,344 | $461,122,316 |
| Asset Impairment Charge | $55,049,991 | $82,013,252 | $113,470,389 | $78,622,622 |
| Depreciation Amortization Depletion | $505,561,140 | $492,079,510 | $501,067,263 | $461,723,372 |
| Depreciation And Amortization | $505,561,140 | $492,079,510 | $501,067,263 | $461,723,372 |
| Earnings Losses From Equity Investments | $8,987,754 | $-41,568,360 | $-70,778,560 | $-114,589,365 |
| Gain Loss On Sale Of PPE | $2,246,938 | $1,123,469 | $7,864,284 | $-1,944,725 |
| Net Income From Continuing Operations | $690,933,558 | $498,820,325 | $231,434,655 | $379,747,195 |
| Common Stock Payments | - | $0 | $0 | $-3,886,080 |
| Sale Of Business | - | - | $0 | $102,654,751 |
Fetched: 2026-10-20